Clinical Trials Directory

Trials / Completed

CompletedNCT04891822

ERAS After Bariatric Surgery in Morbidly Obese

Enhanced Recovery After Bariatric Surgery(ERAS) in the Morbidly Obese Using Evidence-Based Clinical Pathways: A Prospective Observational Non-randomized Comparative Study

Status
Completed
Phase
Study type
Observational
Enrollment
54 (actual)
Sponsor
Seoul National University Bundang Hospital · Academic / Other
Sex
All
Age
19 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Recently, the number of bariatric surgery is increasing but ERAS (Enhanced Recovery After Surgery) protocol for bariatric surgery needs revision with evidence. So we investigated usefulness of ERAS protocol for bariatric surgery in morbidly obese patients.

Detailed description

Patients undergoing elective laparoscopic bariatric surgery are going to be recruited and divided into 2 groups: Group E will receive ERAS protocol, and Group C will receive standard perioperative care. ERAS protocol comprises 8 hours of fasting and ingestion of oral carbohydrate 2 hour before surgery, TIVA(Total intra-venous anesthesia), TAP(transversus abdominis plane) block and IV-PCA using NSAIDs after surgery, and resumption of oral intake 2 hour after surgery. Conventional anesthesia is composed of 8 hours of fasting, inhalation anesthesia, IV-PCA using NSAIDs, and resumption oral intake 6 hour after surgery. In both groups, gastric ultrasonography will be used to measure gastric volume before surgery. Functional hospital stay will be recorded from the end of surgery until all discharge criteria had been met. Pain scores will be recorded at 30 minutes, 4 hours, and 24 hours after surgery. Also, nausea and vomiting, time to ambulation, will be documented. After the patients are discharged, their charts are going to be reviewed and their medical expenses will be documented.

Conditions

Interventions

TypeNameDescription
PROCEDUREERAS protocolE: ERAS protocol C: control

Timeline

Start date
2021-06-02
Primary completion
2022-02-24
Completion
2022-02-28
First posted
2021-05-18
Last updated
2024-01-16

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04891822. Inclusion in this directory is not an endorsement.